Applied Molecular Transport Inc.
Cholix toxin-derived fusion molecules for oral delivery of biologically active cargo
Last updated:
Abstract:
The present disclosure relates to pharmaceutical compositions comprising a non-naturally occurring fusion molecule and one or more pharmaceutically acceptable carriers, formulated for oral delivery to a subject, and designed to provide for improved, effective therapies for treatment of, e.g., inflammatory diseases, autoimmune diseases, cancer, metabolic disorders, and growth deficiency disorders.
Status:
Grant
Type:
Utility
Filling date:
14 Dec 2018
Issue date:
29 Sep 2020